Emerging OSA Treatments Your Patients Will Ask About: Medications, Next-generation CPAP, and Airway Exercises

Saturday, October 17, 2026

9:30 AM - 10:30 AM PT

Location: 403B

Moderator(s)

Yi Cai, MD

Director of Sleep Surgery
Columbia University
New York, New York, United States

Panelist(s)

Eric J. Kezirian, MD, MPH

Professor-in-Residence
UCLA
Los Angeles, CA, United States
AM

Atul Malhotra, MD

Professor; Vice Chair of Medicine for Research; Research Chief of pulmonary, critical care, sleep
UCSD, United States
MZ

Michelle Zeidler, MD

Professor
UCLA, United States

Disclosure(s):

Eric J. Kezirian, MD, MPH:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

Obstructive sleep apnea (OSA) management is expanding beyond CPAP and surgery, and patients increasingly ask otolaryngologists about new therapies. This panel provides an evidence-informed update on emerging OSA treatments and how to counsel patients. Experts will review pharmacologic options, including oral agents targeting OSA pathophysiology (e.g., atomoxetine-aroxybutynin, AD109) and weight-loss medications (GLP-1 and dual GLP-1/GIP agonists, e.g., tirzepatide). Panelists will also discuss evolving PAP technologies, including FDA-approved KairosPAP (KPAP). Finally, the panel will critically review muscle-based and myofunctional approaches marketed to patients, emphasizing evidence quality, candidate selection, and realistic outcomes.

Learning Objectives:

Summarize the evidence for GLP-1 or dual GLP-1/GIP agonists and emerging oral agents in the treatment of OSA.
Distinguish newer PAP technologies (e.g., KPAP) from traditional CPAP.
Examine the role of muscle-based approaches in OSA care.